Clinical trial
A Single-arm, Multiple Centers, Phase II Study Evaluating Rituximab in Combination With Chidamide and Lenalidomide for Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL)
NCT04319601 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Multiple Centers, Phase II Study Evaluating Rituximab in Combination With Chidamide and Lenalidomide for Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL)
- Lead sponsor
- Zhejiang Cancer Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- March 13, 2020
- Completion date
- December 31, 2022
- Enrollment
- 26 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
angioimmunoblastic t-cell lymphoma, chemotherapeutic toxicity, chemotherapy effect